Lindsay Fischer is an editor at ONN. She specializes in healthcare, nursing, and cancer treatment, focusing on drug approvals and treatment strategies. Lindsay's work has been featured in Targeted Oncology, Cancer Network, CURE Media Group, OncLive, Oncology Nursing News, and Wiley.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lindsay Fischer's consistent coverage of healthcare and pharmaceutical topics, with a focus on data-driven insights and expert commentary, indicates that she is likely to be responsive to pitches offering in-depth analysis or interviews from reputable experts in the field. With a strong emphasis on citing data, providing evidence-based research or access to credible sources will enhance the chances of effective outreach.
As Lindsay does not have a specified geographic focus, pitches should address international developments within healthcare and pharmaceuticals. Additionally, given her frequent use of press releases as content sources, organizations promoting new studies or drug approvals may find success by sharing their latest findings for potential coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lindsay Fischer
Beth Sandy, MSN, CRNP, discusses some of the challenges that may be associated with molecular testing, and how oncology nurses can help play a role in ensuring that the reports are received.
By: Lindsay Fischer
Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.
The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.
By: Lindsay Fischer
What are the implications of new approvals for oncology nurses specializing in melanoma?
By: Lindsay Fischer
Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.
By: Lindsay Fischer
Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.
By: Lindsay Fischer
Neoadjuvant chemotherapy allowed 79% of patients with early-stage I/IIA rectal cancer to pursue organ-sparing excision surgery, potentially preserving their quality of life and bowel function.
By: Lindsay Fischer
Patients with non–small cell lung cancer who received toripalimab experienced significant improvements in progression-free survival and overall survival.
